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Purpose of the study
The persisting concern of mitochondrial toxicity and the
potential development of cardio-metabolic toxicity from
nucleoside analogues has prompted clinicians to consider
alternative treatment strategies. Here we investigate the
efficacy, safety and tolerability of a nucleoside-sparing
regimen consisting of nevirapine and boosted lopinavir in
'The NRTI-sparing Study'.
Methods
In this prospective, 48-week, two-centre study, 40 patients
were recruited to receive lopinavir/ritonavir (LPV/r) soft
gel capsules (SGC) (533/133 mg BID) plus nevirapine
(NVP) (200 mg BID). Once HIV-RNA was <50 copies/ml,
patients were allowed to switch to the new LPV/r tablet
formulation (400/100 mg BID); this was not considered a
switch in the analyses. Fasting lipids, CD4 count, and
HIV-1 RNA were performed on days 1, 4 and 7 and weeks
2, 4, 12, 24, 36 and 48. Analyses were intention-to-treat
(ITT; switch & missing = failure) and on treatment.
Summary of results
Patients were predominantly male (85%) and Caucasian
(65%) with a median (range) age of 37 years (23, 69). The
one non-ART-naïve patient had received NRTI mono-
therapy previously. At baseline the median (range) CD4
count and HIV viral load (VL) were 201 cells/mm3 (8,
614) and 5 log copies/ml (3.5, 6), respectively. At 24 and
48 weeks (ITT), 26 patients (65%; 95% CI 46–77) and 20
patients (50%; 95% CI 32–64) achieved HIV-RNA<50
copies/ml, respectively. These values rose to 26/31 (84%;
CI 65–94) and 20/25 (79%) in an on treatment (OT)
analysis (missing = excluded). At 48 weeks, in an OT anal-
ysis, median (range) CD4 change was +155 (-3, +534)
cells/mm3 and the median (IQR) change from baseline in
total cholesterol, LDL-cholesterol, HDL-cholesterol and
triglycerides was +0.7 (+0.1, +1.8), +0.4 (-0.3, +0.8), +0.3
(+0.1, +0.5) and +0.6 (+0.2, +1.4), respectively. Fifteen
patients switched to the LPV/r tablet formulation. Two
patients developed AIDS-defining illnesses and discontin-
ued the study drugs; two died (unrelated to study drug);
two developed a rash (one Stevens-Johnson syndrome),
and one developed NNRTI resistance. Overall, 15 individ-
uals discontinued treatment. The median (range) time to
discontinuation was 24 weeks (2, 43).
Conclusion
In this predominantly antiretroviral-naïve cohort, at 48
weeks 79% of the patients remaining on the NRTI-sparing
regimen had HIV-RNA <50 copies/ml. These figures are
comparable with previously reported figures in similar
treatment strategies.
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